Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Citius Oncology, Inc. (CTOR) had Return on Tangible Equity of -55.19% for the most recently reported fiscal year, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-24.76M |
|
-- |
|
-- |
|
$23.52M |
|
$-23.52M |
|
$-0.18M |
|
$-23.70M |
|
$-23.70M |
|
$-24.76M |
|
$-24.76M |
|
$-24.76M |
|
$-24.76M |
|
$-23.52M |
|
$-23.52M |
|
73.27M |
|
73.27M |
|
$-0.34 |
|
$-0.34 |
|
| Balance Sheet Financials | |
$27.54M |
|
-- |
|
$73.40M |
|
$100.94M |
|
$49.49M |
|
$3.80M |
|
$6.59M |
|
$56.08M |
|
$44.87M |
|
$44.87M |
|
$44.87M |
|
83.51M |
|
| Cash Flow Statement Financials | |
$-5.49M |
|
$-5.75M |
|
$15.17M |
|
$0.00M |
|
$3.92M |
|
$3.92M |
|
$8.32M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.56 |
|
-- |
|
-- |
|
0.08 |
|
0.30 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-5.49M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-55.19% |
|
|
Return on Tangible Equity |
-55.19% |
-24.53% |
|
-50.88% |
|
$0.54 |
|
$-0.07 |
|
$-0.07 |
|